{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:57:41Z","timestamp":1789595861512,"version":"build-2803163510"},"reference-count":79,"publisher":"Medknow","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Postgrad Med"],"published-print":{"date-parts":[[2003]]},"DOI":"10.4103\/0022-3859.926","type":"journal-article","created":{"date-parts":[[2009,3,21]],"date-time":"2009-03-21T01:42:22Z","timestamp":1237599742000},"page":"61","source":"Crossref","is-referenced-by-count":43,"title":["Recent understanding in the treatment of visceral leishmaniasis."],"prefix":"10.4103","volume":"49","author":[{"given":"E","family":"Rosenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"key":"key-10.4103\/0022-3859.926-1","first-page":"239","volume-title":"The increase in risk factors of leishmaniasis worldwide","author":"Desjeux","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-2","first-page":"862","volume-title":"The epidemic of visceral leishmaniasis of Upper Nile, Southern Sudan: course and impact from 1984 to 1994","author":"Seaman","year":"1996","journal-title":"Int J Epidemiol"},{"key":"key-10.4103\/0022-3859.926-3","unstructured":"WHO: Leishmania\/HIV co-infection, South-western Europe 1990-1998. Geneva: World Health Organization; mimeographed document 2000 WHO\/LEISH\/2000.42."},{"key":"key-10.4103\/0022-3859.926-4","unstructured":"WHO. Report of the consultative meeting on Leishmania\/HIV coinfection, Rome, 6-7 Setember, 1994. Geneva: World Health Organization; mimeographed document 1995 WHO\/LEISH\/95.35\/1995."},{"key":"key-10.4103\/0022-3859.926-5","first-page":"159","volume-title":"Visceral leishmaniasis and HIV-1 co-infection in Southern France","author":"Rosenthal","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-6","first-page":"182","volume-title":"Leishmania\/HIV interaction: immunopathogenic mechanisms","author":"Wolday","year":"1999","journal-title":"Parasitol Today"},{"key":"key-10.4103\/0022-3859.926-7","first-page":"1093","volume-title":"HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania","author":"Rosenthal","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-8","first-page":"84","volume-title":"Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy","author":"Rosenthal","year":"2001","journal-title":"AIDS"},{"key":"key-10.4103\/0022-3859.926-9","first-page":"296","volume-title":"Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies","author":"Herwaldt","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-10","first-page":"560","volume-title":"Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies","author":"Berman","year":"1988","journal-title":"Rev Infec Dis"},{"key":"key-10.4103\/0022-3859.926-11","first-page":"1104","volume-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of indian epidemic","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-12","first-page":"1928","volume-title":"Sodium antimony gluconate, amphotericin, and myocardial damage","author":"Thakur","year":"1998","journal-title":"Lancet"},{"key":"key-10.4103\/0022-3859.926-13","first-page":"562","volume-title":"Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection","author":"Santos","year":"2000","journal-title":"An Med Interna"},{"key":"key-10.4103\/0022-3859.926-14","first-page":"312","volume-title":"Randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan","author":"Veeken","year":"2000","journal-title":"Trop Med Int Health"},{"key":"key-10.4103\/0022-3859.926-15","first-page":"668","volume-title":"Ethiopian visceral leishmaniasis: generic and propriarity sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome","author":"Ritmeijer","year":"2001","journal-title":"Trans R Soc Med Hyg"},{"key":"key-10.4103\/0022-3859.926-16","first-page":"388","volume-title":"Comparison of generic and propiarity sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya","author":"Moore","year":"2001","journal-title":"Bull World Health Organ"},{"key":"key-10.4103\/0022-3859.926-17","first-page":"139","volume-title":"A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate","author":"Sundar","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-18","first-page":"841","volume-title":"Novel methods for the encapsulation of meglumine antimoniate into liposomes","author":"Frezard","year":"2000","journal-title":"Braz J Med Biol Res"},{"key":"key-10.4103\/0022-3859.926-19","first-page":"1256","volume-title":"Amphotericin versus pentamidine in antimony-unresponsive kala-azar","author":"Mishra","year":"1992","journal-title":"Lancet"},{"key":"key-10.4103\/0022-3859.926-20","first-page":"609","volume-title":"A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis","author":"Das","year":"2001","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/0022-3859.926-21","first-page":"715","volume-title":"Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone","author":"Seaman","year":"1994","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-22","first-page":"429","volume-title":"prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis","author":"Thakur","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-23","doi-asserted-by":"crossref","unstructured":"Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000;94:432-3.","DOI":"10.1016\/S0035-9203(00)90131-7"},{"key":"key-10.4103\/0022-3859.926-24","first-page":"2185","volume-title":"Clinical and experimental advances in treatment of visceral leishmaniasis","author":"Murray","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0022-3859.926-25","first-page":"556","volume-title":"Allopurinol in the treatment of visceral leishmaniasis","author":"Kager","year":"1981","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-26","doi-asserted-by":"crossref","unstructured":"Chunge CN, Gachihi G, Muigai R. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985;79:715-8.","DOI":"10.1016\/0035-9203(85)90200-7"},{"key":"key-10.4103\/0022-3859.926-27","first-page":"204","volume-title":"Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India","author":"Jha","year":"1983","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-28","first-page":"611","volume-title":"Treatment of visceral leishmaniasis with meglumine and allopurinol","author":"Ragusa","year":"1993","journal-title":"Am J Dis Child"},{"key":"key-10.4103\/0022-3859.926-29","first-page":"319","volume-title":"Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases","author":"Thakur","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-30","first-page":"200","volume-title":"Short course, cost-effective treatment with Amphotericin B-fat emulsion cures visceral leishmaniasis","author":"Sundar","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-31","first-page":"1061","volume-title":"Liposomal amphotericin B in drug-resistant visceral leishmaniasis","author":"Davidson","year":"1991","journal-title":"Lancet"},{"key":"key-10.4103\/0022-3859.926-32","first-page":"938","volume-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-33","first-page":"309","volume-title":"Treatment of kala azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days","author":"Dietze","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-34","first-page":"762","volume-title":"Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex (ABLC)","author":"Sundar","year":"1996","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-35","first-page":"133","volume-title":"Short course low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony","author":"Sundar","year":"1997","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0022-3859.926-36","first-page":"319","volume-title":"Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study","author":"Thakur","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-37","first-page":"435","volume-title":"Chemotherapy of leishmaniasis and trypanosomiasis: advances and failures","author":"Gradoni","year":"1996","journal-title":"Curr Opin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-38","first-page":"1191","volume-title":"Leishmaniasis","author":"HerwaldtT","year":"1999","journal-title":"Lancet"},{"key":"key-10.4103\/0022-3859.926-39","first-page":"133","volume-title":"Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)","author":"Russo","year":"1996","journal-title":"J Infection"},{"key":"key-10.4103\/0022-3859.926-40","first-page":"625","volume-title":"Successful treatment of antimony resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus","author":"Torre-Cisneros","year":"1993","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-41","first-page":"1308","volume-title":"Visceral leishmaniases in renal transplant recipients: successful treatment with liposomal amphotericin B (Ambisome)","author":"Boletis","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-42","first-page":"419","volume-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B randomized trial","author":"Sundar","year":"2001","journal-title":"BMJ"},{"key":"key-10.4103\/0022-3859.926-43","first-page":"2633","volume-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","author":"Croft","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"key-10.4103\/0022-3859.926-44","first-page":"1630","volume-title":"Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice","author":"Kuhlencord","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0022-3859.926-45","first-page":"654","volume-title":"Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in Balb\/c mice","author":"Le","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0022-3859.926-46","first-page":"1041","volume-title":"The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei","author":"Croft","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0022-3859.926-47","first-page":"S91","volume-title":"Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites","author":"Urbina","year":"1997","journal-title":"Parasitology"},{"key":"key-10.4103\/0022-3859.926-48","first-page":"795","volume-title":"Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms","author":"Murray","year":"2000","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-49","first-page":"288","volume-title":"Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis","author":"Murray","year":"2000","journal-title":"Infect Immun"},{"key":"key-10.4103\/0022-3859.926-50","first-page":"3235","volume-title":"Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine","author":"Murray","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0022-3859.926-51","first-page":"1821","volume-title":"Trial of oral miltefosine for visceral leishmaniasis","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"key-10.4103\/0022-3859.926-52","first-page":"589","volume-title":"Oral treatment of visceral leishmaniasis with miltefosine","author":"Sundar","year":"1999","journal-title":"Ann Trop Med Parasitol"},{"key":"key-10.4103\/0022-3859.926-53","first-page":"1795","volume-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","author":"Jha","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0022-3859.926-54","first-page":"1110","volume-title":"Short-course of oral miltefosine for treatment of visceral leishmaniasis","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-55","first-page":"1739","volume-title":"Oral miltefosine for indian leishmanisis","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0022-3859.926-56","first-page":"684","volume-title":"Human leishmaniasis:clinical, diagnostic, and chemotherapeutic developments in the last 10 years","author":"Berman","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-57","first-page":"2057","volume-title":"Donn\u00e9es r\u00e9centes sur le traitement de la leishmaniose visc\u00e9rale","author":"Gangneux","year":"1999","journal-title":"Presse Med"},{"key":"key-10.4103\/0022-3859.926-58","first-page":"158","volume-title":"Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches","author":"Murray","year":"2000","journal-title":"Int J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-59","first-page":"1034","volume-title":"Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis","author":"Sherwood","year":"1994","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0022-3859.926-60","first-page":"685","volume-title":"Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi","author":"Dietze","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-61","first-page":"622","volume-title":"Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma and interleukin-2-independent","author":"Murray","year":"1991","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-62","first-page":"1627","volume-title":"Effect of treatment with interferon-gamma alone in visceral leishmaniasis","author":"Sundar","year":"1995","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-63","first-page":"16","volume-title":"Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma","author":"Badaro","year":"1990","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0022-3859.926-64","first-page":"1117","volume-title":"Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis","author":"Sundar","year":"1997","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0022-3859.926-65","unstructured":"Harrat Z, Addadi K, Belkaid M, Tabet-Derraz O. La leishmaniose visc\u00e9rale en Alg\u00e9rie. Recensement des cas de leishmaniose visc\u00e9rale. Bull Soc Path E 1992;85:296-301."},{"key":"key-10.4103\/0022-3859.926-66","first-page":"33","volume-title":"Human visceral leishmaniasis in Alpes-Maritimes, France: epidemiological characteristics for the period 1985-1992","author":"Marty","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-67","first-page":"298","volume-title":"Leishmania and human immunodeficiency virus coinfection: the first ten years","author":"Alvar","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"key-10.4103\/0022-3859.926-68","doi-asserted-by":"crossref","unstructured":"Kubar J, Marty P, Lelievre A, Quaranta JF, Staccini P, Caroli-Bosc C, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+T-lymphocyte counts. AIDS 1998;12:2147-53.","DOI":"10.1097\/00002030-199816000-00009"},{"key":"key-10.4103\/0022-3859.926-69","first-page":"383","volume-title":"Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy","author":"Soriano","year":"2000","journal-title":"AIDS"},{"key":"key-10.4103\/0022-3859.926-70","first-page":"2946","volume-title":"Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy","author":"Berenguer","year":"2000","journal-title":"AIDS"},{"key":"key-10.4103\/0022-3859.926-71","first-page":"391","volume-title":"Epidemiological, clinical and therapeutic features of kala-azar (including post kala-azar dermal leishmaniasis)","author":"Thakur","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0022-3859.926-72","unstructured":"Gradoni L, Bryceson A, Desjeux P. Treatment of mediterranean visceral leishmaniasis. Bull World Health Organization. 1995;73:191-7."},{"key":"key-10.4103\/0022-3859.926-73","unstructured":"73. Anonymous. Conclusions and recommendations of the IVth WHO joint meeting on Leishmania-HIV co-infections. Parasite 2001;8: 376-9."},{"key":"key-10.4103\/0022-3859.926-74","doi-asserted-by":"crossref","unstructured":"Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999;13:1063-9.","DOI":"10.1097\/00002030-199906180-00009"},{"key":"key-10.4103\/0022-3859.926-75","first-page":"25","volume-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","author":"Berman","year":"1998","journal-title":"Bull World Health Organization"},{"key":"key-10.4103\/0022-3859.926-76","first-page":"849","volume-title":"Drug resistance in Indian visceral leishmaniasis","author":"Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"key":"key-10.4103\/0022-3859.926-77","first-page":"1101","volume-title":"Treatment of visceral leishmaniasis: a review of current treatment practices","author":"Marty","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/0022-3859.926-78","first-page":"928","volume-title":"A policy for leishmaniasis with respect to the prevention and control of drug resistance","author":"Bryceson","year":"2001","journal-title":"Trop Med Int Health"},{"key":"key-10.4103\/0022-3859.926-79","first-page":"1793","volume-title":"Kala-azar-Progress against a neglected disease","author":"Murray","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T20:42:14Z","timestamp":1558212134000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jpgmonline.com\/text.asp?2003\/49\/1\/61\/926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.4103\/0022-3859.926","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]}}}